Tag: EU HTA regulation
DARWIN EU 2.0 & JCA PICO Strategy: Streamlining Multi-State RWE
Mastering DARWIN EU 2.0 Interoperability for JCA Compliance: The Technical Blueprint for Multi-State Real-World Evidence The European market access landscape is undergoing its most profound structural disruption since the centralization of regulatory approvals. The rollout of the European Union Health Technology Assessment (EU-HTA) regulation has effectively shifted the goalposts for pharmaceutical manufacturers. No longer can…
Drug Value with RWE and Role of AI in EU’s JCA
Drug Value with Real-World Evidence (RWE): Opportunities, Challenges, and the Role of AI in EU’s Joint Clinical Assessment (JCA) What is Real-World Evidence and Why It Matters in the EU HTA Landscape Real-World Evidence (RWE) refers to health data gathered outside of traditional clinical trials. It comes from sources like electronic health records, patient registries,…
Pharma Market Access 2025: HTA, U.S. Drug Pricing, and Tariffs
Global Pharma Market Access Under Pressure Pharma market access is no longer just a regulatory hurdle, it’s a geopolitical challenge. With the EU’s new HTA regulation, U.S. pricing reforms, potential Trump tariffs, and legislative shifts in key markets, pharmaceutical access is facing cross-border disruption. Manufacturers must realign their strategies to sustain revenue and reach patients.…
